ClinicalTrials.gg

Program

Fluorine F 18 FAPI-74

Its studies are mostly in Esophageal Neoplasms · Gastrointestinal Neoplasms, led by SOFIE.

Furthest: phase 3, since Oct 14, 20253 company-led studies, 2 open or runningNext primary completion: Aug 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SOFIE32 open or runningphase 3since Oct 14, 2025Nov 29, 2022Aug 30, 2027phase 3 · NCT07217704

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2022First study: phase 2 study in Gastrointestinal NeoplasmsFirst studyNCT05641896 · 112 enrolled · United States
  2. Oct 14, 20252 phase 3 studiesNCT07217717, NCT07217704

Ahead

  1. Aug 30, 2027Primary completion: phase 3 study in Esophageal NeoplasmsNCT07217704
  2. Dec 31, 2027Primary completion: phase 3 study in Pancreatic Ductal Adenocarcinoma (PDAC)NCT07217717

TargetBeta

FAP →read by rule
“A radioconjugate composed of FAPI-74, a quinoline-based fibroblast activation protein (FAP)-targeted tracer belonging to the group of FAP inhibitors (FAPi) ”NCIt, by rule

Other programs on FAP

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
Fluorine F 18 FPyQCPruleBraccophase 21
HRS-6768Jiangsu HengRui Medicinephase 21
Anti-FAP Antibody-drug Conjugate OMTX705ruleoncomatryx-biopharma-s-lphase 12
Gallium Ga 68 NNS309Novartisphase 12
Actinium Ac 225 RTX-2358ruleratio-therapeutics-incphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050ruleImmunomephase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07217717Pancreatic Ductal Adenocarcinoma (PDAC) · United States3RecruitingDec 31, 2027200
NCT07217704Esophageal Neoplasms · United States3RecruitingAug 30, 2027200
NCT05641896Gastrointestinal Neoplasms · United States2CompletedJun 30, 2025112

How it is read

Names in the registry

  • “[18F]FAPI-74 PET/CT”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.